WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 226

Legislative bill overview

SB 226 is a Hawaii bill relating to prescription drugs that was introduced in the 2025 legislative session. The bill was referred to the Health and Human Services (HHS) and Consumer Protection and Commerce (CPN) committees but has been carried over to the 2026 session without passage, suggesting either ongoing deliberation or insufficient support for advancement in the current session.

Why is this important

Prescription drug policy directly affects healthcare affordability and access for Hawaii residents. Bills in this category typically address drug pricing, insurance coverage, pharmaceutical transparency, or pharmacy regulations—issues that impact both individual patients and the state's healthcare system costs.

Potential points of contention

  • Specifics unknown: Without the bill text available, the exact provisions remain unclear; it could involve price controls, generic drug promotion, or coverage mandates that stakeholders may dispute differently
  • Industry vs. consumer interests: Pharmaceutical companies may oppose cost-limiting measures while consumer advocates push for affordability protections
  • Implementation feasibility: Depending on provisions, enforcement mechanisms and compliance costs for pharmacies and insurers could face scrutiny

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.